Réunion satellite du Symposium international sur l’angiogenèse rétinienne et choroïdienne

 

Le 5 novembre 2020, 134 participants se sont réunis pour assister en ligne à la première réunion satellite du Symposium international sur l’angiogenèse rétinienne et choroïdienne.

Objectifs pédagogiques

L’objectif principal de la Réunion scientifique satellite du Symposium international en angiogénèse rétinienne et choroïdienne est de donner l’occasion aux étudiants, résidents, professeurs, cliniciens et personnel paramédical l’opportunité de se familiariser avec les plus récentes avancées dans des domaines précis de l’ophtalmologie qui s’appliquent non seulement à la dégénérescence maculaire liée à l’âge, mais également aux rétinopathies ischémiques, telles dans le diabète et la prématurité.

Plus précisément, les objectifs pédagogiques de cet événement sont les suivants :
– Expliquer aux étudiants, résidents, professeurs, chercheurs et cliniciens les concepts en émergence dans le domaine de l’angiogenèse rétinienne et choroïdienne et les implications pour la pratique clinique.
– Identifier et souligner différentes études cliniques et applications cliniques contemporaines d’envergure en angiogénèse de la rétine et de la choroïde.
– Reconnaitre les altérations génétiques responsables de malformations vasculaires.
– Développer des connaissances en thérapie génique d’application ophtalmique.
– Se familiariser avec les problèmes du métabolisme de la rétine pouvant mener à la cécité.
– Découvrir le potentiel thérapeutique de découvertes scientifiques.
– Explorer les découvertes sur des maladies du système nerveux central dans le but de les appliquer dans des désordres ophtalmiques analogues.
– Favoriser les échanges d’idées sur les recherches récentes portant sur l’angiogenèse rétinienne et choroïdienne entre étudiants de tous les niveaux (stagiaires, étudiants de premier cycles, M. Sc., Ph. D., SPD, étudiants en médecine, résidents, fellows), professeurs, chercheurs et cliniciens. Ceci inclut les interactions et discussions approfondies des sujets présentés.
– Établir de nouvelles collaborations dans le but d’améliorer la compréhension des pathologies oculaires vasoproliférantes et en conséquence les soins donnés.

Educational Goals

The main objective of the Satellite Scientific Meeting of the International Symposium on Retinal and Choroidal Angiogenesis is to provide an opportunity for students, residents, professors, clinicians and paramedics to familiarize themselves with the most recent advances in specific areas of ophthalmology that apply not only to age-related macular degeneration, but also to ischemic retinopathies, such in diabetes and prematurity.

More specifically, the educational goals of this event are as follows:

– Explain to students, residents, professors, researchers and clinicians the emerging concepts in the field of retinal and choroidal angiogenesis and implications for clinical practice.
– Identify and highlight different clinical studies and contemporary large-scale clinical applications in retinal and choroidal angiogenesis.
– Recognize genetic alterations responsible for vascular malformations.
– Develop knowledge in ophthalmic gene therapy.
– Familiarize oneself with the problems of retinal metabolism that can lead to blindness.
– Discover the therapeutic potential of scientific discoveries.
– Explore discoveries about diseases of the central nervous system with the aim of applying them to similar ophthalmic disorders.
– Promote the exchange of ideas on recent research on retinal and choroidal angiogenesis among students at all levels (trainees, undergraduate, PhD, Post-Doc trainees, medical students, residents, fellows), professors, researchers and clinicians. This includes in-depth interactions and discussions of the topics presented.
– Establish new collaborations with the aim of improving the understanding of vasoproliferatives ocular pathologies and consequently the care given.

Revivez ou découvrez les présentations des 5 prestigieux invités:

(Le visionnement des conférences en différé ne donne pas le droit à des crédits.)

 

Mot de bienvenue – Dr Sylvain Chemtob, M.D., Ph. D., Université de Montréal, Canada

 

Noncanonical TGFb Signaling is Crucial for Specialized Neuroretina Tip-Cells Sprouting and Blood-Retina Barrier Formation – Alexandre Dubrac, Ph. D., Université de Montréal, Canada

En découvrir davantage sur Alexandre Dubrac, Ph. D.

Assistant Professor, Faculty of Medicine, Department of Pathology and Cell Biology, University of Montreal
Researcher, Centre de recherche du Centre hospitalier universitaire Sainte-Justine

Le Dr. Alexandre Dubrac a obtenu son doctorat à l’Université de Bordeaux I, où il a travaillé avec le Professeur Andreas Bikfalvi sur l’angiogénèse tumorale. Il s’est ensuite joint comme chercheur postdoctoral au groupe du Professeur Anne Eichmann à la Yale School of Medicine où il a exploré la fonction des régulateurs de guidance axonale lors du bourgeonnement des vaisseaux sanguins. Entre d’autres, ses travaux ont démontré la nouvelle fonction de Slit2 et Robo1&2 dans la néovascularisation de la rétine. Il a été chercheur associé à l’Université Yale, ou ses travaux ont porté sur l’interaction cellule entothéliale-péricyte au cours du développement vasculaire et de la rétinopathie ischémique. Le Dr. Dubrac a rejoint le CHU st-Justine en tant que chercheur adjoint sous octroi à l’Université de Montréal en 2018 et son laboratoire s’intéresse à identifier de nouveaux mécanismes régulant l’angiogenèse de la rétine et du cerveau lors du développement et dans des pathologies ischémiques.



Contributions of Neurovascular Abnormalities to Autism Spectrum Disorders – Baptiste Lacoste, Ph. D., Université d’Ottawa, Canada

En découvrir davantage sur Dr. Baptiste Lacoste, Ph. D.

Assistant Professor, Faculty of Medicine, Department of Cellular & Molecular Medicine, University of Ottawa
Scientist, The Ottawa Hospital Research Institute, Neuroscience Program,
University of Ottawa Brain and Mind Research Institute

My research background in neuroscience and postdoctoral training in vascular biology allow me to bridge the gap between these two disciplines, through a solid foundation in anatomical, physiological, biochemical and genetic approaches. I have developed a unique expertise focused on elucidating mechanisms of cerebrovascular plasticity and neurovascular interactions in health and disease. The brain, which is highly dependent on a steady supply of oxygen and nutrients from the blood stream, is particularly vulnerable to inherited or acquired cerebrovascular conditions. In this context, research goals from my lab include investigating:
1) How cerebrovascular networks develop;
2) What mechanisms underlie their plasticity;
3) How vascular integrity and function are altered in neurological conditions; and
4) How targeting cerebrovascular plasticity may offer therapeutic options throughout life. Identifying key cellular and molecular mediators of cerebrovascular health is an essential pre-requisite for developing novel therapeutic strategies.



Brain arteriovenous malformations: genetic origin, signaling and potential therapies – Ivan Radovanovic, M. D., Ph. D., FMH – University of Toronto

 

En découvrir davantage sur Ivan Radovanovic, M.D., Ph. D., FHM

Associate Professor, Division of Neurosurgery, Toronto Western Hospital
University Health Network and University of Toronto
Scientist, Toronto Western Research Institute

Dr. Ivan Radovanovic joined the Toronto Western Hospital as of January 2013. Dr. Radovanovic obtained his medical degree and began neurosurgery residency training at the University of Geneva, Switzerland in 1998. In 2002, he completed a diploma in molecular biology and genetics from the University of Zurich, and in 2003 he completed the equivalent of a PhD at the Institute of Neuropathology at the University of Zurich. He subsequently resumed residency training at Geneva University Hospitals, graduating from the program in 2007. In 2008, Dr. Radovanovic joined Toronto Western Hospital as a clinical fellow in neuro-oncology/skull base surgery and then also completed a clinical fellowship in cerebrovascular surgery. Between 2010-2011, Dr. Radovanovic was staff neurosurgeon at Geneva University Hospitals, Department of Clinical Neurosciences, Division of Neurosurgery. In 2013, he was recruited to the Division of Neurosurgery with a staff appointment at Toronto Western Hospital. He is currently an Assistant Professor in the Department of Surgery at The University of Toronto. His research is focused on the surgical management of ruptured and unruptured aneurysms, AVMs and dural arteriovenous fistulae, using minimally invasive techniques such as supraorbital and lateral supraorbital craniotomies. His research laboratory is within the Toronto Western Research Institute and focuses on the developmental signaling and genetics of cerebral arteriovenous malformations and brain tumors.



Metabolism of the visual cycle and the activity of lecithin retinol acyltransferase from the retinal pigment epithelium, Dr Christian Salesse, Ph. D., Université Laval, Canada

En découvrir davantage sur Dr. Christian Salesse, Ph. D.

Tenured Professor, Department of Ophthalmology and Otolaryngology / Head and Neck Surgery, Université Laval
Director of Research, Department of Ophthalmology, Université Laval
Researcher, Centre universitaire d’ophtalmologie du Centre de recherche du CHU de Québec, Université Laval, Hôpital St-Sacrement

After his graduate studies in biophysics at Université du Québec à Trois-Rivières (UQTR), Christian Salesse was a postdoctoral fellow at the Johannes Gutenberg Universität in Mainz (Germany). He then became an assistant professor at UQTR in 1990 and full professor in 1998. He moved to the Université Laval in 2002 as the head of the ophthalmology research unit at the Centre de recherche du CHUL as well as the head of research of the department of ophthalmology. He was a Junior 1, Junior 2, Senior and National FRQS research fellow between 1990 and 2006. He moved to the Hôpital du St-Sacrement of the Centre de recherche du CHU de Québec-Université Laval in 2011 as the head of the theme Santé de la vision until 2018. He was an invited professor for various periods of time at several universities (Montpellier, Rennes and Bordeaux in France, Lisbon in Portugal, Changchun in China).



First Good News of 2020: Gene Therapy in Retinopathies – Dr Flavio Rezende, M.D., Ph. D., Université de Montréal, Canada

En découvrir davantage sur Dr. Flavio Rezende, M.D., Ph. D.

Clinical Associate Professor, Department of Ophthalmology, University of Montreal
Ophthalmologist and Surgeon Retinologist, Centre universitaire d’ophtalmologie, Hôpital Maisonneuve-Rosemont Hospital

As an Associate Professor from the Department of Ophthalmology, University of Montreal (UdeM), I lead the clinical/surgical side of our translational research team at the Centre Universitaire d’Ophtalmologie, Maisonneuve-Rosemont hospital (CUO-HMR), Montreal, Quebec, Canada. My main focus is on surgical management of complicated vitreoretinal diseases, academic teaching, and surgical translational research.

As a vitreoretinal surgeon, I have been developing and improving complex vitreoretinal surgical techniques to manage vitreoretinal diseases.

On the academic side, I have been in charge of the Vitreoretinal Fellowship Program from the Retina Service, Department of Ophthalmology, UdeM for 5 years (2013-2018).

As a surgical translational researcher, I have developed surgical techniques to obtain vitreous biopsies in an ambulatory setting, providing instrumental material for our Neuro-Vascular Biology Research Unit. We are currently building a biobank for vitreous and aqueous humor samples.

For the past 5 years, I have been involved with Retinal Chip implant, developing an innovative surgical technique for a new generation retinal chip.

And in the past year I have served as Clinical Director at CUO-HMR and, as such, I have been committed to bringing further innovation to benefit our patients. We are becoming now one of the first centers in Canada for gene therapy for previously untreatable retinal conditions.



 

Mot de la fin – Dr Sylvain Chemtob, M.D., Ph. D., Université de Montréal, Canada